Demand and Supply Manager
Thermo Fisher ScientificSalary not specified
- Full Time
- Junior (1 to 2 years)
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, HealthcareIndustries
Requirements
The Director of Supply Chain Planning requires a Bachelor's degree and at least 10 years of experience in supply chain planning, preferably within the pharmaceutical or biotechnology industry. Strong analytical and problem-solving skills are essential, along with experience in long-range planning and scenario-based analysis. Familiarity with GMP and regulatory requirements is also necessary.
Responsibilities
The Director will collaborate with cross-functional teams to develop and maintain a reliable demand and supply plan, ensuring uninterrupted clinical supply and commercial launch readiness. They will monitor external manufacturing site capacities, identify opportunities for supply chain optimization, lead scenario planning to mitigate risks, and manage relationships with third-party suppliers. Additionally, the Director will author SOPs, perform data analysis, and ensure compliance with regulatory standards.
Skills
Supply Chain Planning
Demand Planning
Inventory Management
Production Planning
Risk Assessment
Scenario Planning
Cross-functional Collaboration
CMC
Logistics
Quality
Clinical Operations
Commercial
Dyno Therapeutics
Develops AI-optimized gene therapy vectors
About Dyno Therapeutics
Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.
Watertown, MassachusettsHeadquarters
2018Year Founded
$106MTotal Funding
SERIES_ACompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
51-200Employees